![]() ![]() Two mouse monoclonal antibodies (MoAbs) were established and used as catching antibodies. HGF enzyme-linked immunosorbent assay (ELISA).Ī sandwich HGF ELISA was developed in our laboratory. Control samples were obtained from 61 healthy age- and sex-matched individuals. s–M-protein and treatment periods were recorded from their medical records. Three patients, from whom serum had been drawn at regular intervals (≥1 sample/6 months) over a period of at least 18 months, were included for a detailed analysis of change in HGF levels over time. In these patients, relapse was defined as the time from which treatment was reindicated. In 9 of the 13 patients in the latter group, serum drawn at the time of relapse was also available. Sixteen of these patients belonged to the NMSG study group, and 13 of them were additional patients from the Section of Hematology, University of Trondheim. For the analysis of changes in HGF levels from diagnosis to response, serum samples from 29 patients (13 with complete response and 9 with partial 6 minor response) were included. 5Īll serum samples from the time of diagnosis were taken before the initiation of treatment. 4 In normal tissue c-met is expressed primarily in epithelial cells, but it has also been detected on a small fraction of cells in the bone marrow, 5, 6 half of which were identified as hematopoietic precursor cells because of their expression of CD34. The receptor for HGF is a transmembrane tyrosine kinase that is encoded by the proto-oncogene c-met. ![]() This property led to the designation “scatter factor”, 3 a name that is still used synonymously with HGF. 2 In vitro HGF has the ability to cause destruction of tight junctions, thereby inducing spread of confluent cells. Hepatocyte growth factor (HGF) was originally purified by its ability to cause growth stimulation of hepatocytes 1 but is now known as a mitogenic, motogenic, and morphogenic factor with potential involvement in diverse biological processes. The cause of these features is only partly understood, but production of soluble factors by the myeloma cells is likely to be involved. It is associated with production of monoclonal immunoglobulins, painful bone destruction, anemia, hypercalcemia, and renal dysfunction. MULTIPLE MYELOMA is a disorder of unknown origin of clonal malignant plasma cells. HGF was a prognostic factor in patients with high levels of β2-microglobulin. Measurement of HGF may identify a group of patients with poor response to melphalan-prednisone treatment and short survival. We conclude that HGF may be a useful follow-up parameter in myeloma patients. In serial samples HGF was higher at the time of diagnosis and relapse (median 0.57 ng/mL and 0.52 ng/mL, respectively P = .0018) than at response (median 0.24 ng/mL, P = .008). In the subgroup of patients with β2-microglobulin levels less than or equal to 6 mg/L, high versus low HGF was a prognostic factor when a multivariate Cox regression analysis was performed. In a univariate Cox regression analysis, HGF was a significant predictor of mortality ( P = .02). In the group with elevated HGF levels 46% of the patients reached plateau phase, as compared with 60% of the patients with low HGF levels ( P = .005), and the median survival time was 21 and 32 months, respectively ( P = .002). HGF was elevated at diagnosis in 43% of myeloma patients compared with healthy controls (median 1.00 ng/mL and 0.44 ng/mL, respectively P < .00001). Serum from 398 myeloma patients at diagnosis and serial samples from 29 patients were analysed for hepatocyte growth factor (HGF). ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |